3rd Quarter - Report

WUXI BIOLOGICS USA LLC for WUXI BIOLOGICS USA LLC

Period 3rd Quarter 2024 Filed Oct 21, 2024 Signed by Elizabeth Steele

Official filing
Firm
WUXI BIOLOGICS USA LLC
Client
WUXI BIOLOGICS USA LLC
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 8333, the BIOSECURE Act; S. 3558 Prohibiting Foreign Access to American Genetic Data Information Act of 2024; communications related to company operations and CRDMO industry, including descriptions of corporate structure, business units, and data handling.

Foreign entity interest: WuXi Biologics Ireland Limited, WuXi Biologics Investments Limited, WuXi Biologics (Cayman) Inc., WuXi Biologics (Hong Kong) Limited, and WuXi Biologics (Shanghai) Co., Ltd

LobbyistCovered position, as disclosed
WILLIAM AITCHISON —
ELIZABETH STEELE —

Contacted: SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Treasury, Dept of; Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES

Bills named: S. 3558 (118th), H.R. 8333 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.